Compare Credo Technology Group Holding Ltd (CRDO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Viatris Inc — how do they compare? Credo Technology Group Holding Ltd trades at $265.59 (market cap $50.01B), while Viatris Inc trades at $16.17 (market cap $18.49B). The key difference: Credo Technology Group Holding Ltd is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays a 2.98% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | VTRS | |
|---|---|---|
Market Cap | $50.01B | $18.49B |
Sector | Technology | Health |
52-Week High | $302.52 | $17.86 |
52-Week Low | $87.81 | $9.49 |
Enterprise Value | $48.59B | $30.61B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $268.16, up 11.76% in 24 hours, with a bullish technical signal and strong institutional interest. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.16 exceeding expectations. Revenue surged to $436.78 million in 2025, and net income margin expanded to 35.37% in 2026. Positive news highlights Credo's role in AI infrastructure, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financials, but risks include premium valuations (P/E 98.68) and customer concentration. Analyst consensus is bullish with a $285.42 price target. Investors should monitor execution risks and market volatility amid high growth expectations.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
